Andisheh-Tadbir A, Mardani M, Pourshahidi S, Nezarati K, Bahadori P. Prognostic value of matrix metalloproteinase-9 expression in oral squamous cell carcinoma and its association with angiogenesis. J Clin Exp Dent. 2016;8(2):e130-5.

 

doi:10.4317/jced.52712

http://dx.doi.org/doi:10.4317/jced.52712

 

References

1. Scully C. Oral squamous cell carcinoma; from an hypothesis about a virus, to concern about possible sexual transmission. Oral Oncol. 2002;38:227-34.
http://dx.doi.org/10.1016/S1368-8375(01)00098-7

PMid:11978544

 

2. Kim SH, Cho NH, Kim K, Lee JS, Koo BS, Kim JH, et al. Correlations of oral tongue cancer invasion with matrix metalloproteinases (MMPs) and vascular endothelial growth factor (VEGF) expression. J Surg Oncol. 2006;93:330-7.
http://dx.doi.org/10.1002/jso.20461
PMid:16496371

 

3. Lopes FF, da Costa Miguel MC, Pereira AL, da Cruz MC, de Almeida Freitas R, Pinto LP, et al. Changes in immunoexpression of E-cadherin and beta-catenin in oral squamous cell carcinoma with and without nodal metastasis. Ann Diagn Pathol. 2009;13:22-9.
http://dx.doi.org/10.1016/j.anndiagpath.2008.07.006
PMid:19118778

 

4. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990;82:4-6.
http://dx.doi.org/10.1093/jnci/82.1.4
PMid:1688381

 

5. El-Shahat M, Lotfy M, Fahmy L, Abouel-Nour MF, El-Kenawy Ael M. Prognostic value of microvessel density, matrix metalloproteinase-9 and p53 protein expression in esophageal cancer. J Egypt Natl Canc Inst. 2004;16:224-30.
PMid:16116499

 

6. Kademani D, Lewis JT, Lamb DH, Rallis DJ, Harrington JR. Angiogenesis and CD34 expression as a predictor of recurrence in oral squamous cell carcinoma. J Oral Maxillofac Surg. 2009;67:1800-5.
http://dx.doi.org/10.1016/j.joms.2008.06.081
PMid:19686913

 

7. Fox SB, Harris AL. Histological quantitation of tumour angiogenesis. Apmis. 2004;112:413-30.
http://dx.doi.org/10.1111/j.1600-0463.2004.apm11207-0803.x
PMid:15563306

 

8. Dallas NA, Samuel S, Xia L, Fan F, Gray MJ, Lim SJ, et al. Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res. 2008;14:1931-7.
http://dx.doi.org/10.1158/1078-0432.CCR-07-4478
PMid:18381930

 

9. Nikiteas NI, Tzanakis N, Theodoropoulos G, Atsaves V, Christoni Z, Karakitsos P, et al. Vascular endothelial growth factor and endoglin (CD-105) in gastric cancer. Gastric Cancer. 2007;10:12-7.
http://dx.doi.org/10.1007/s10120-006-0401-8
PMid:17334712

 

10. Vilen ST, Salo T, Sorsa T, Nyberg P. Fluctuating roles of matrix metalloproteinase-9 in oral squamous cell carcinoma. Scientific World Journal. 2013;2013:920595.
http://dx.doi.org/10.1155/2013/920595
PMid:23365550 PMCid:PMC3556887

 

11. Hadler-Olsen E, Fadnes B, Sylte I, Uhlin-Hansen L, Winberg JO. Regulation of matrix metalloproteinase activity in health and disease. Febs j. 2011;278:28-45.
http://dx.doi.org/10.1111/j.1742-4658.2010.07920.x
PMid:21087458

 

12. Bjorklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta. 2005;1755:37-69.
http://dx.doi.org/10.1016/j.bbcan.2005.03.001

PMid:15907591

 

13. Fridman R, Toth M, Pena D, Mobashery S. Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res. 1995;55:2548-55.

PMid:7780967

 

14. Backstrom JR, Tokes ZA. The 84-kDa form of human matrix metalloproteinase-9 degrades substance P and gelatin. J Neurochem. 1995;64:1312-8.
http://dx.doi.org/10.1046/j.1471-4159.1995.64031312.x
PMid:7532211

 

15. Franchi A, Santucci M, Masini E, Sardi I, Paglierani M, Gallo O. Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck. Cancer. 2002;95:1902-10.
http://dx.doi.org/10.1002/cncr.10916
PMid:12404284

 

16. Ohashi K, Nemoto T, Nakamura K, Nemori R. Increased expression of matrix metalloproteinase 7 and 9 and membrane type 1-matrix metalloproteinase in esophageal squamous cell carcinomas. Cancer. 2000;88:2201-9.
http://dx.doi.org/10.1002/(SICI)1097-0142(20000515)88:10<2201::AID-CNCR2>3.0.CO;2-N

PMid:10820340

 

17. Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol. 1999;189:300-8.
http://dx.doi.org/10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C

PMid:10547590

 

18. Baker EA, Bergin FG, Leaper DJ. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging. Br J Surg. 2000;87:1215-21.
http://dx.doi.org/10.1046/j.1365-2168.2000.01531.x
PMid:10971431

 

19. Katayama A, Bandoh N, Kishibe K, Takahara M, Ogino T, Nonaka S, et al. Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis. Clin Cancer Res. 2004;10:634-40.
http://dx.doi.org/10.1158/1078-0432.CCR-0864-02

PMid:14760086

 

20. Werner JA, Rathcke IO, Mandic R. The role of matrix metalloproteinases in squamous cell carcinomas of the head and neck. Clin Exp Metastasis. 2002;19:275-82.
http://dx.doi.org/10.1023/A:1015531319087
PMid:12090467

 

21. Engsig MT, Chen QJ, Vu TH, Pedersen AC, Therkidsen B, Lund LR, et al. Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones. J Cell Biol. 2000;151:879-89.
http://dx.doi.org/10.1083/jcb.151.4.879
PMid:11076971 PMCid:PMC2169432

 

22. Eshghyar N, Mohammadi N, Rahrotaban S, Motahhary P, Vahedi Vaez SM. Endoglin (CD105) positive microvessel density and its relationship with lymph node metastasis in squamous cell carcinoma of the tongue. Arch Iran Med. 2011;14:276-80.
PMid:21726105

 

23. Mărgăritescu C, Pirici D, Stîngă A, Simionescu C, Raica M, Mogoantă L, et al. VEGF expression and angiogenesis in oral squamous cell carcinoma: an immunohistochemical and morphometric study. Clin Exp Med. 2010;10:209-14.
http://dx.doi.org/10.1007/s10238-010-0095-4
PMid:20376688

 

24. Miyahara M, Tanuma J, Sugihara K, Semba I. Tumor lymphangiogenesis correlates with lymph node metastasis and clinicopathologic parameters in oral squamous cell carcinoma. Cancer. 2007;110:1287-94.
http://dx.doi.org/10.1002/cncr.22900

PMid:17674352

 

25. Chien CY, Su CY, Hwang CF, Chuang HC, Hsiao YC, Wu SL, et al. Clinicopathologic significance of CD105 expression in squamous cell carcinoma of the hypopharynx. Head Neck. 2006;28:441-6.
http://dx.doi.org/10.1002/hed.20364
PMid:16320363

 

26. Chien CY, Su CY, Hwang CF, Chuang HC, Chen CM, Huang CC. High expressions of CD105 and VEGF in early oral cancer predict potential cervical metastasis. J Surg Oncol. 2006;94:413-7.
http://dx.doi.org/10.1002/jso.20546
PMid:16967447

 

27. Rau KM, Huang CC, Chiu TJ, Chen YY, Lu CC, Liu CT, et al. Neovascularization evaluated by CD105 correlates well with prognostic factors in breast cancers. Exp Ther Med. 2012;4:231-6.
PMid:23139713 PMCid:PMC3460296

 

28. Niers TM, Richel DJ, Meijers JC, Schlingemann RO. Vascular endothelial growth factor in the circulation in cancer patients may not be a relevant biomarker. PLoS One. 2011;6:e19873.
http://dx.doi.org/10.1371/journal.pone.0019873
PMid:21637343 PMCid:PMC3102663

 

29. Riedel F, Gotte K, Schwalb J, Bergler W, Hormann K. Expression of 92-kDa type IV collagenase correlates with angiogenic markers and poor survival in head and neck squamous cell carcinoma. Int J Oncol. 2000;17:1099-105.
http://dx.doi.org/10.3892/ijo.17.6.1099

PMid:11078794

 

30. Kurizaki T, Toi M, Tominaga T. Relationship between matrix metalloproteinase expression and tumor angiogenesis in human breast carcinoma. Oncol Rep. 1998;5:673-7.
http://dx.doi.org/10.3892/or.5.3.673

PMid:9538174